Ensysce Biosciences Files to Sell 652,439 Shares of Common Stock for Holders
Express News | Watching Ensysce Biosciences; Zacks Small-Cap Research Gives Stock $18.45 Price Valuation
Ensysce Biosciences Prices 315,188 Shares at $3.49 in Registered Direct Offering
Ensysce Biosciences Announces PAINWeek 2025 Symposium
12 Health Care Stocks Moving In Thursday's After-Market Session
Ensysce Biosciences GAAP EPS of -$2.90 Misses by $0.17
10-K: FY2024 Annual Report
8-K: Ensysce Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results
Ensysce Biosciences Announces Continued Enrollment in PF614-MPAR Trial
Express News | Ensysce Biosciences Announce SInterim Data From Second Trial Evaluating PF614-MPAR Showing A 100mg Dosage Form Provided Overdose Protection
Ensysce Biosciences Regains Compliance With Nasdaq
Ensysce Biosciences Regains Full Nasdaq Compliance
Ensysce Biosciences Regains Full Compliance With Nasdaq
Express News | Ensysce Biosciences Secures Commercial Supplier For PF614-MPAR Overdose Protection Drug, Fully Establishing Supply Chain With GMP Nafamostat From Aurore Life Sciences
Trading Halt: Halt Status Updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption Times
Ensysce Biosciences Trading Halted, News Pending
Express News | Trading Halt: Halted at 7:50:00 P.m. ET - Trading Halt: Halt News Pending
Ensysce Biosciences To Carry Out 1-for-15 Reverse Stock Split On December 6th, 2024
Ensysce Biosciences Announces Partnership With Specialty Drug Manufacturer
Express News | Ensysce Biosciences Initiates PARtnership With A Drug Manufacturer For The Development And Commercial Launch Of PF614 And PF614-MPAR, Including A $10M Commitment From The Drug Manufacturer